Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Effects of Protein and Amino Acid Supplementation on Physical Performance in Patients With Chronic Heart Failure - A Systematic Review and Meta-Analysis.

Circulation reports·2026
Same author

Long-term Safety and Efficacy of Bempedoic Acid in Japanese Patients with Hypercholesterolemia: the CLEAR-J LONG.

Journal of atherosclerosis and thrombosis·2025
Same author

Three-Year Outcome of Drug Coated Balloon Angioplasty Following Atherectomy for Severely Calcified Coronary Lesions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Successful Treatment of Infective Endocarditis at 33 Weeks' Gestation Causing Acute Left Heart Failure.

Clinical case reports·2025
Same author

A male patient with pseudoxanthoma elasticum caused by isodisomy of chromosome 16 containing a nonsense variant of the <i>ABCC6</i> gene: A quarter-century treatment experience.

Atherosclerosis plus·2025
Same author

Circulating type IV collagen 7S concentrations are associated with left atrial remodeling indices in patients with atrial fibrillation.

The Journal of international medical research·2025
Same journal

Optimization of Infectious Disease Treatment via Clinical Practice-Based Personalized Therapy and Big Data Analysis.

Biological & pharmaceutical bulletin·2026
Same journal

Development of Nucleic Acid-Loaded Nanobubbles for Ultrasound-Mediated Therapeutic Applications.

Biological & pharmaceutical bulletin·2026
Same journal

An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

Biological & pharmaceutical bulletin·2026
Same journal

A Quantitative in Vitro Framework Reveals State-Dependent Pharmacological Responses to Repeated Inflammatory Stimulation in Synovial Fibroblasts.

Biological & pharmaceutical bulletin·2026
Same journal

Pinolenic Acid Inhibits Prostanoid TP Receptor-Mediated Contraction in Porcine Coronary Arteries.

Biological & pharmaceutical bulletin·2026
Same journal

Lipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Mice.

Biological & pharmaceutical bulletin·2026
查看所有相关文章

相关实验视频

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

特拉斯图祖马布心脏毒性:机制和管理

Minoru Wakasa1, Miharu Masaki1, Kouji Kajinami1

  • 1Department of Cardiology, Kanazawa Medical University.

Biological & pharmaceutical bulletin
|August 31, 2025
PubMed
概括
此摘要是机器生成的。

它可以引起心脏问题. 了解心脏风险,诊断和治疗对于患者的安全至关重要.

关键词:
心脏毒性人类表皮生长因子受体2型其他药物

更多相关视频

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

相关实验视频

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

科学领域:

  • 癌症学
  • 心脏病学
  • 药理学

背景情况:

  • 特拉斯图祖马布是广泛使用的乳腺癌治疗方法.
  • 它带有心脏毒性的风险,包括心律失常,心肌病和心力衰竭.
  • 目前正在阐明特鲁祖马布诱导的心脏毒性的机制,可能涉及红细胞瘤基因B2受体.

研究的目的:

  • 审查与抗人类表皮生长因子受体2治疗相关的心脏毒性机制,诊断方法和治疗/预防策略.
  • 为了解决特斯图祖马布对心脏的不良影响提供全面的概述.

主要方法:

  • 对特斯图祖马布心脏毒性的现有文献的综述.
  • 讨论诊断工具,如心声学,心脏生物标志物 (troponin I,NT-proBNP) 和MRI.
  • 分析当前和新兴的药物干预措施.

主要成果:

  • 心脏毒性是治疗trastuzumab的一个重要问题.
  • 通过心脏功能评估和生物标志物进行早期诊断是可能的.
  • 已有的心力衰竭治疗方法 (如β阻塞剂,ACE抑制剂) 和较新的药物 (如RNAI,SGLT2抑制剂) 是有前途的.
  • 也正在研究PCSK9抑制剂的心脏保护作用.

结论:

  • 需要多方面的方法来有效地控制特斯图祖马布的心脏毒性.
  • 监测心脏功能和使用适当的诊断工具至关重要.
  • 药物干预,包括既有和新疗法,是预防和治疗心脏不良事件的关键.